SHR5428

SHR5428 is a potent, selective, and orally bioavailable noncovalent CDK7 inhibitor with an enzymatic IC50 of 2.3 nM. It demonstrates robust cellular activity in triple-negative breast cancer models, such as MDA-MB-468 cells, with an IC50 of 6.6 nM. This inhibitor is a valuable chemical probe for researching transcriptional regulation and cell cycle progression in oncology.